Cancer

  • About the area
  • Groups

The area of ​​cancer research has been structured in two different aspects: the clinical and the translational laboratory research.

Within the clinic, we can currently find four lines of research that have to do with the volume of incidence and prevalence of neoplastic disease, such as: breast cancer, lung cancer, urological tumors and gastrointestinal tumors. Each of them is made up of professionals who are dedicated to the diagnosis, treatment and monitoring of specific neoplasms.

In all lines there is extensive experience in conducting national and international studies. Many of the members belong to different national and international scientific societies, which allows them to be in touch with the latest scientific advances. Work is currently underway to increase the specific number of clinical research lines.

Within translational research, the goal has been to detect tumor prognostic factors that allow us to predict the survival of our cancer patients in their different types and stages. The translational research laboratory has become a reference in the detection of miRNA in serum and tissue, and has gained experience in colon cancer.

Currently, collaboration has begun with the Digestive Service, to start the study of miRNA in gastric cancer, and with the Pulmonology Service, for the study of miRNA in lung cancer. Work is also underway to increase cooperation with all those professionals who are working on some type of cancer.

Area coordination
Miquel Àngel Seguí

msegui@tauli.cat

Group A1G4 - Biomedical research in cancer

Accreditation level: Consolidated group

The Biomedical Research Group on Cancer is a group with a long research career. It is made up of professionals from different medical and surgical specialties, which allows us to tackle cancer research in a multidisciplinary and global way, addressing the prognostic, clinical and molecular factors of cancer, as well as developing new treatment options.

The incidence of cancer is gradually increasing worldwide, as well as being one of the leading causes of death in our environment. The importance of having new knowledge about the behavior of the disease is a challenge of obvious relevance.

The group participates with national and international companies and groups, such as SEOM, GEICAM, SOGUG, TTD, GEMCAD and EORTC, which allows the development of projects in a wide field with which results are achieved with a high degree of evidence.

Lines of research

  • Research into new drugs and effective therapies in patients with breast, thoracic, urological and thyroid cancer of the breast.
  • Search for supportive treatment for patients.

Composition of the group

Enrique Gallardo Diaz (Cap de grup)

Doctoral research staff

  • Bejarano González, Natalia
  • Fernández Morales, Luís Antonio
  • Garcia Borobia, Francisco Javier
  • Garcia Monforte, Neus
  • Guirao Garriga, Francisco Javier
  • Pericay Pijaume, Carles
  • Seguí Palmer, Miquel Àngel
  • Muñoz Rodríguez, Jesús

Predoctoral

  • Castañer González, Eva
  • Dalmau Pórtulas Elsa
  • Domínguez García, Arturo
  • Garcia Garcia, Yolanda
  • García Rojo, Darío
  • Hannaoui Hadi, Naim
  • Macias Declara, Ismael
  • Medarde Ferrer, Meritxell

Non-doctoral research staff

  • Aparicio Rodríguez, Óscar
  • Bonfill Abella, Teresa
  • Llort Pursals, Gemma
  • López Mestres, Aida
  • Medina Argení, Sandra
  • Pleasures Gago, Angeles
  • Ribera Fernández, Paula
  • Ribot Luna, Laia
  • Vila Martínez, Laia
  • Yébenes Marsal, Mireia

Associated professionals

  • Andreu Magarolas, Marta
  • Barcons Vilaplana, Santi
  • Cabrera Romero, José Manuel
  • Gallardo Cistaré, Xavier
  • Giner Joaquin, Júlia
  • Malet Munté, Antoni
  • Nogueiras Pérez, Rosa
  • Pérez Riverola, Víctor
  • Prenafeta Moreno, Mario
  • Puig Domingo, Jordi
  • Ribot Berenguer, Teresa

Group A1G5 - Molecular and Translational Research in Cancer

Accreditation level: Popup group 

2017 SGR 473

The Molecular and Translational Research Group on Cancer carries out various projects aimed at research at the cellular and molecular level of cancer with particular interest in the search for biomarkers for the diagnosis, prognosis and prediction of response to treatment.

The aim is that the results of this research can be transferred to clinical practice and be able to offer cancer patients a more personalized and appropriate treatment for each type of tumor.

The group is made up of postdoctoral and predoctoral researchers, mostly from the pathology department of our Hospital. It also has close internal and external collaborations with researchers from various prestigious groups, which allows a multidisciplinary approach to research projects.

Lines of research

  • Identification of a metabolomic profile for the prognosis of early-stage colon cancer.
  • Research on lncRNAs in colon cancer and evaluation of their use as biomarkers for prognosis.
  • Characterization of the metabolome in patients with advanced ovarian cancer and correlation with the response to Bevacizumab.
  • Characterization of the microbiome and metabolome in patients with unresectable stage III lung cancer: New tool to predict the efficacy of immunotherapy.
  • Gene characterization of Thyroid Cancer to improve its diagnosis and treatment.
  • Molecular classification of Endometrial Cancer, prognostic and predictive value.

Composition of the group

Anna Brunet Vega (Group leader)

Doctoral research staff

  • Bella Cueto, M. Rosa
  • Costa Trachsel, Irmgard
  • Ferreres Piñas. Joan Carles

Predoctoral

  • Blázquez Maña, Carmen María
  • Carrera Salas, Ruben
  • Papaleo, Natalia
  • Reques Llanos, Armando

Associated professionals

  • Casalots Casado, Alex
  • Escoda Giral, Rosa
  • Sáez Artacho, Empar

A1G6 Group - Innovation in Cancer

Accreditation level: Popup group

The Cancer Innovation group consists of different basic lines of research that are aimed at improving current diagnostic tests to make them more reliable and predictable, as well as investigating new, less invasive potential treatments than those currently available for cancer. worse prognosis.

We hope that all the innovative results obtained in the laboratories will go into clinical phase in the shortest possible time, always thinking of the positive impact that this would have on the medical field, and obviously on the patients. For this reason, we focus our research on:

  • The use of innovative cellular models that allow us to obtain more accurate results than conventional models, while reducing experimentation with animals.
  • The development of new treatments based on technology and drugs already used medically, but looking for mechanisms that improve their effectiveness, and at the same time, allow for more accurate and safe therapies.
  • The use of artificial intelligence (AI) to improve current diagnostic techniques.

All this is possible thanks to the collaborations, both internal and external, that we have established with other prestigious groups, and which allow us to create the synergies needed to continue to grow innovation in the field of cancer research. .

Lines of research

  • Investigation of the role of technological innovation in both the diagnosis and treatment of neoplasms in diagnostic support (IA) and in new non-pharmacological treatments.
  • Exploration of more realistic (and comparable to neoplasm) cell cultures, which take into account cell-cell and cell-microenvironment interactions.
  • Study of magnetic hyperthermia for the treatment of resistant tumors.
  • Optimization of chemotherapy and radiotherapy treatments for brain tumors.

Composition of the group

Silvia Gil Duran (Group leader)

Doctoral research staff

  • Bernà Roqueta, Lluís
  • Caresia Aroztegui, Paula
  • Moragas Solanes, Mercedes

Non-doctoral research staff

  • Del Riego Ferrari, Javier
  • Estela Herrero, Jordi
  • Martín Olóriz, Amaya

Associated professionals

  • Codina Aroztegui, Clara
  • Escribano Alcántara, Fernanda
  • Martin Miramon, Joan Carles
  • Tortajada Giménez, Lidia
  • Villajos Fernández, María Teresa
Privacy preferences

When you visit our website, your browser may store information about specific services, usually in the form of cookies. Here you can change your privacy preferences. Please note that blocking certain types of cookies may affect your experience on our website and the services we offer.

Enable / disable Google Analytics tracking code
Enable / disable Google Fonts
Turn Google Maps on / off
Enable / disable embedded videos
This website uses cookies, mainly from third party services. You can edit your privacy preferences and / or accept the use of cookies.